Company Name:BeiGene Ltd.
CEO: John V. Oyler

Sector: Healthcare
Industry:Biotechnology

Exchange: Nasdaq Global Select

Country: USA

Description: BeiGene Ltd is a biopharmaceutical company engaged in the discovery and development of molecularly targeted and immuno-oncology drugs for the treatment of cancer. Its product includes BGB-3111, BGB-A317 and BGB-290 and one immuno-oncology agent.


Key numbers

Market Capitalization:11971905750
Shares Outstanding: 60387923.076923005
Float: 60337801.1007692
Next Earning Date:2020-02-25
TTm EPS: -13.8549
TTm Dividend Rate:
200 days moving average:134.27
50 days moving average: 143.38
One day percent Change: 42.74



2018-03-31, 2018-06-30, 2018-09-30, 2018-12-31,
2018-03-31, 2018-06-30, 2018-09-30, 2018-12-31,
2015-12-31, 2016-12-31, 2017-12-31, 2018-12-31,
2015-12-31, 2016-12-31, 2017-12-31, 2018-12-31,